TMAO, the gut compound blamed for heart disease, may protect men from colon cancer after weight-loss surgery

If you or someone in your family has had gastric bypass surgery, you may have heard that it can raise levels of a gut-bacteria byproduct called TMAO, the same compound doctors warn about for heart health. A new study flips that story on its head for a different organ: in mice modeling human colorectal cancer, higher circulating TMAO after bariatric surgery-like exposure actually slowed tumor growth, but only in males. The finding does not change any current medical advice, but it reframes a molecule that gut health researchers have treated almost entirely as a villain.

Key takeaways

• In a genetically engineered mouse model of colorectal cancer, dietary TMAO supplementation cut colon tumor volume, but only in male mice, not female mice.
• The protection tracked with how much TMAO stayed in the bloodstream: males retained more of it, and higher circulating TMAO was linked to smaller tumors and less TNF-alpha driven inflammation in the gut lining.
• This is mouse and cell-line evidence, not proof that TMAO prevents colon cancer in people; a separate study in different mice found TMAO promoted tumors by a different route, showing the effect is highly context-dependent.
• Bariatric surgery's actual link to colorectal cancer risk in humans remains mixed in the research literature, and this study did not test whether surgery patients' cancer outcomes differ by sex.

TMAO cuts colon tumor growth in male mice, not female mice

Researchers at Imperial College London and Emory University found that dietary TMAO (trimethylamine N-oxide, a compound made when gut bacteria break down choline and carnitine from food and the liver converts it further) significantly reduced colon tumor volume in male mice from a genetically altered strain that mimics human colorectal cancer, but had no significant effect in female mice from the same strain. The mice, engineered to develop intestinal tumors similar to hereditary human colorectal cancer, were fed a normal diet supplemented with TMAO for six weeks (males) or eight weeks (females). Fewer TMAO-fed males developed tumors at all compared to untreated males, and the tumors that did form were smaller.

TMAO is best known as the gut-microbial metabolite that multiple large studies have linked to a higher risk of heart attack, stroke, and other cardiovascular problems, largely because it promotes artery-clogging plaque and blood clotting. This study did not find a cardiovascular benefit, and it does not contradict that heart-disease research. What it adds is a separate, organ-specific finding: in this colon cancer model, the same molecule that harms arteries appeared to protect colon tissue, at least in males.

Why this matters to anyone tracking bariatric surgery and gut health

The study's starting point was a real clinical observation: Roux-en-Y gastric bypass (RYGB), one of the most common weight-loss surgeries, reliably raises circulating TMAO levels afterward, and some studies have suggested bariatric surgery patients face a higher long-term risk of colorectal cancer. That has left patients and doctors with an uncomfortable open question about whether the surgery's microbiome side effects contribute to cancer risk. This study is the first to test, mechanistically, whether TMAO itself drives tumor growth or restrains it, and the answer it found, at least in this animal model, was the opposite of the assumption: higher TMAO tracked with less tumor growth, not more, in males.

Anyone managing a personal or family history of colorectal cancer, inflammatory bowel disease, or considering bariatric surgery may have seen TMAO mentioned as a surgery side effect worth worrying about. This study does not settle that worry either way for humans, but it complicates the idea that rising TMAO after surgery is automatically bad news for the colon.

How the researchers tested it: a genetic mouse model plus a small human cohort

The team first measured TMAO in blood from 16 real bariatric surgery patients (11 who had RYGB, 5 who had gastric banding) at Emory University, confirming that TMAO rose significantly six months after RYGB but not after the less invasive banding procedure. They then turned to a genetically altered mouse strain, called FabplCre;Apc15lox/+, bred to develop colon tumors that closely resemble human sporadic and hereditary colorectal cancer. A total of 94 mice (46 male, 48 female) were split into TMAO-supplemented and control groups and tracked for tumor development. Finally, the researchers exposed mouse immune cells (macrophages) and human colon cancer cells (the HCT-116 line) directly to TMAO in lab dishes to probe the mechanism. Combining a patient cohort, a genetic animal model, and cell culture work is a stronger design than any one piece alone, though the human arm only measured blood chemistry, not cancer outcomes.

What the sex difference might mean, and what it does not mean, for readers

The protective effect tracked closely with how much TMAO stayed in an animal's bloodstream rather than how much it was fed. Male mice retained significantly more circulating TMAO than females did after the same supplementation, and that retention was directly, statistically tied to protection: in males, more TMAO in the blood correlated with smaller tumors, while females mostly excreted the extra TMAO in urine and saw no benefit. The likely mechanism is immune, not a direct anti-cancer effect on tumor cells themselves. TMAO lowered the share of immune cells producing TNF-alpha (tumor necrosis factor alpha, an inflammatory signaling molecule that has separately been shown to help drive colorectal cancer growth) in the tissue lining the colon, and the same suppression showed up when researchers exposed lab-grown immune cells to TMAO directly. Notably, TMAO did not change how fast the human colon cancer cells themselves grew or accumulated DNA damage in a dish, suggesting the effect works through calming inflammation around a tumor rather than attacking cancer cells directly.

None of this supports taking a TMAO supplement, eating more of the choline- and carnitine-rich foods (red meat, eggs, certain fish) that raise TMAO, or treating rising TMAO after bariatric surgery as protective for an individual patient. The study was not designed to test any of those interventions in people.

A conflicting mouse study complicates the picture

The most important limitation the researchers themselves flagged: a separate, previously published study in a different genetically engineered mouse strain (Apcmin/+ females) found that orally given TMAO promoted intestinal tumor growth, through an entirely different biological pathway. The authors' own conclusion is that TMAO's effect on colorectal cancer risk is context-dependent, varying by the specific mouse model, sex, and how the compound was delivered, not a settled, one-directional relationship. The human portion of the study was also small (16 patients) and measured blood TMAO levels only, not cancer diagnoses or outcomes, so it cannot say whether bariatric surgery patients' colorectal cancer risk actually differs by sex.

What comes next

The researchers say the logical follow-up is a longer human study tracking bariatric surgery patients' TMAO levels alongside actual colorectal cancer screening outcomes over years, not just six months of blood chemistry. On the mechanism side, they suggest testing whether blocking TNF-alpha signaling directly reproduces the protective effect seen with TMAO, which would strengthen the case that inflammation, not TMAO itself, is the real lever. No clinical trial timeline was announced.

Common Questions

Does this mean TMAO is actually good for me? No. TMAO remains linked to cardiovascular disease risk in multiple large human studies, and this colon cancer finding was sex-specific, animal-based, and contradicted by at least one other mouse study using a different model.

Should I ask my doctor about TMAO if I've had bariatric surgery? If you already have a family or personal history of colorectal cancer, it is reasonable to discuss routine cancer screening timelines with your doctor after bariatric surgery, since surgery itself is separately linked to changes in colorectal cancer risk in some human cohort studies, independent of this new finding.

Why did the effect only show up in males? Male mice retained significantly more TMAO in their bloodstream after supplementation, while females cleared more of it through urine; the protective effect tracked with blood retention, not diet alone, suggesting a sex difference in how the body processes TMAO rather than a sex difference in colon biology itself.

Is TMAO the reason bariatric surgery might lower cancer risk? It is one candidate mechanism this study proposes, but the actual human evidence on whether bariatric surgery raises or lowers colorectal cancer risk is mixed across existing cohort studies, and this paper did not test cancer outcomes in surgery patients directly.

References

1. Yang Bi, Maria Glymenaki, Maria A. Valdivia-Garcia, et al. (2026). Trimethylamine N-oxide, a bariatric surgery-associated host-microbial co-metabolite, reduces colonic tumorigenesis in a sex-dependent manner. Cellular and Molecular Gastroenterology and Hepatology. https://doi.org/10.1016/j.jcmgh.2026.101869
2. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941174/